A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

Por Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Publicado em 2013

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Por Khalifa, J., Ouali, M., Chaltiel, L., Le Guellec, S., Le Cesne, A., Blay, J-Y, Cousin, P., Chaigneau, L., Bompas, E., Piperno-Neumann, S., Bui-Nguyen, B., Rios, M., Delord, J-P, Penel, N., Chevreau, C.
Publicado no BMC Cancer (2015)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

Por Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.
Publicado em 2014